Development of a Bispecific Antibody Targeting Clinical Isolates of Acinetobacter baumannii.

ABSTRACT:

Background

We previously reported developing 2 anticapsular monoclonal antibodies (mAbs) as a novel therapy for Acinetobacter baumannii infections. We sought to determine whether a bispecific mAb (bsAb) could improve avidity and efficacy while maximizing strain coverage in one molecule.

Methods

Humanized mAb 65 was cloned into a single-chain variable fragment and attached to humanized mAb C8, combining their paratopes into a single bsAb (C73). We tested bsAb C73's strain coverage, binding affinity, ex vivo opsonic activity, and in vivo efficacy compared to each mAb alone and combined.

Results

The bsAb demonstrated strain coverage, binding affinity, opsonization, and in vivo efficacy superior to either original mAb alone or combined.

Conclusions

A humanized bsAb

SUBMITTER: Nielsen TB 

PROVIDER: S-EPMC10319980 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature